GLP-1 Medications at Med Spas: Compliance Requirements After the FDA's 2026 Crackdown

Why the GLP-1 Compliance Landscape Just Changed Overnight

GLP-1 receptor agonists — the drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — became the most in-demand category in the med spa industry almost overnight. Weight management services now drive significant revenue at practices across the country, and the market shows no sign of slowing.

But the regulatory environment has caught up just as quickly. In February 2026, the FDA announced new restrictions on ingredients used in unapproved compounded GLP-1 medications and signaled a crackdown on misleading advertising. This follows the agency's 2025 decision to remove semaglutide and tirzepatide from the federal drug shortage list — a move that eliminated the primary legal basis under which most compounding pharmacies had been producing these drugs.

The result: practices that haven't updated their GLP-1 compliance programs since 2024 are likely operating outside federal law right now.

This isn't an abstract regulatory risk. The FDA, FTC, and state medical boards have all opened enforcement actions against med spas and telehealth platforms for GLP-1 violations. Penalties include warning letters, product seizure, civil monetary penalties, and loss of medical licenses.

The Legal Landscape: What Changed and When

The Shortage Listing Was the Exception, Not the Rule

From approximately 2022-2024, FDA placed semaglutide and tirzepatide on the federal drug shortage list. This created a legal pathway for compounding pharmacies — specifically 503A (state-licensed, small-scale) and 503B (federally licensed outsourcing facilities) pharmacies — to produce copies of these drugs when the branded versions were unavailable.

When the FDA officially removed both drugs from the shortage list in early 2025, the legal framework for most compounded GLP-1 production collapsed:

• 503A compounders were required to stop producing compounded semaglutide and tirzepatide essentially immediately — these facilities may only compound when a drug is on the shortage list or when producing patient-specific customizations not commercially available
• 503B outsourcing facilities received a brief wind-down period but were also required to cease bulk production of identical compounded copies
• The only remaining lawful compounding involves specific, documented patient needs that cannot be met by commercially available products (e.g., documented allergy to an inactive ingredient in the branded product)

The FDA's 2026 action went further: restricting specific ingredients (including certain salts and derivatives of semaglutide) that had been used in "workaround" formulations designed to appear compliant while evading the shortage list restrictions.

What This Means for Med Spas Right Now

If your practice was sourcing compounded semaglutide or tirzepatide from a 503A pharmacy after mid-2025, or from any compounder using restricted ingredients, you need legal counsel immediately. This is not a technicality — the FDA has authority to seize product, issue warning letters, and refer cases to the Department of Justice.

Who Can Legally Prescribe GLP-1 Medications at a Med Spa?

GLP-1 drugs are Schedule-exempt prescription medications, meaning they require a valid prescription from a licensed prescriber. The prescriber must have authority in your state and must perform an adequate clinical evaluation before prescribing.

Qualified Prescribers (varies by state)

• Physicians (MD/DO) — can prescribe in all states
• Nurse Practitioners (NP) — can prescribe independently in most states; some require physician collaboration agreement
• Physician Assistants (PA) — can prescribe under physician supervision in most states
• Clinical Pharmacists — can prescribe in a limited number of states under collaborative practice agreements

What "Adequate Clinical Evaluation" Requires

A valid GLP-1 prescription cannot be based on an online questionnaire alone. The prescriber must:

• Review a complete medical history including cardiovascular conditions, thyroid history, pancreatitis, kidney disease, and current medications
• Document the medical necessity — typically BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea)
• Assess contraindications (personal or family history of medullary thyroid carcinoma or MEN2 syndrome)
• Establish a monitoring plan with follow-up intervals
• Obtain and document informed consent

Telehealth evaluations are permissible in most states but must include a live video or audio component. Asynchronous questionnaires without any real-time provider-patient interaction do not constitute adequate prescribing under most state medical practice acts.

Sourcing GLP-1 Medications Legally in 2026

Given the current regulatory environment, med spas have two legally sound options for GLP-1 sourcing:

Option 1: FDA-Approved Branded Products

The safest path. Patients receive a prescription for Wegovy (semaglutide for obesity), Zepbound (tirzepatide for obesity), or the diabetes-indicated versions (Ozempic, Mounjaro). The prescription is filled at a licensed retail or mail-order pharmacy. The med spa provides the injection service — it does not dispense the medication.

Pros: Fully compliant, no regulatory risk, FDA-verified safety and efficacy data
Cons: Higher cost to patients, prior authorization challenges, some patients prefer compounded options

Option 2: Compounded Products from Licensed 503B Facilities

If a 503B outsourcing facility can document that it is producing a compounded version that is not identical to the commercially available product (e.g., a different dosage form, or a formulation for a patient with documented intolerance to an ingredient in the branded product), it may still lawfully compound GLP-1 drugs. This is a narrow exception.

Before sourcing from any 503B compounder, request:

• Current FDA registration certificate
• Most recent FDA inspection report (Form 483) and any warning letters
• Certificate of Analysis (CoA) for each lot you purchase
• Written documentation of the legal basis for their GLP-1 compounding
• Pharmacy's DEA registration (if applicable)

What to Avoid

• 503A pharmacies — legally prohibited from bulk compounding GLP-1 drugs post-shortage
• Online suppliers advertising "research chemicals" or "peptides" — these are not FDA-regulated and pose significant patient safety and legal risks
• International suppliers — importing unapproved drugs is a federal customs and FDA violation
• Any pharmacy that cannot provide a current FDA inspection report — walk away

Dispensing vs. Administering: A Critical Legal Distinction

Many med spas confuse two distinct activities with very different legal requirements:

• Administering = a licensed clinical staff member (RN, NP, PA, MD) injects or otherwise delivers a medication to a patient who has a valid prescription that has already been dispensed
• Dispensing = providing the physical medication to the patient — this is a pharmacy function

Most med spas are licensed to administer medications under a physician's oversight. They are generally not licensed to dispense medications. If your practice is physically handing medication to patients to take home, or if patients are drawing medication from vials you stock on-site, you may be dispensing — which requires pharmacy licensure in most states.

The correct model: the patient obtains their GLP-1 medication from a pharmacy (or it is shipped directly to them from a pharmacy), and they bring it to your practice for injection services.

Florida-Specific Requirements for GLP-1 Programs

Florida med spas face an additional layer of regulatory scrutiny specific to GLP-1 programs:

Pending Pharmacy Licensing Legislation

Florida lawmakers introduced legislation in early 2026 requiring med spas that use prescription medications — explicitly including GLP-1 drugs — to obtain a pharmacy license from the Florida Board of Pharmacy. While this bill had not yet passed as of February 2026, it signals the direction of state enforcement and should be monitored closely by any Florida practice offering weight management services.

Existing Florida Requirements

• Medical director oversight — all GLP-1 prescribing must occur under the supervision of a licensed Florida physician acting as medical director
• Delegation rules — a Florida physician may delegate injection administration to an RN or ARNP but must have a documented delegation protocol and supervision structure in place
• Documentation standards — Florida Administrative Code requires specific content in medical records for patients receiving prescription drug therapy
• Advertising restrictions — Florida Statute 458.331 prohibits false, deceptive, or misleading advertising by licensed practitioners, which extends to GLP-1 outcome claims

Required Documentation for Every GLP-1 Patient

If you offer GLP-1 services, your chart for each patient must include:

Pre-Treatment Records

• Completed medical intake form covering relevant history (cardiovascular, endocrine, GI, kidney, thyroid, family history of MTC/MEN2)
• Current medication list — screened for interactions (especially insulin, sulfonylureas)
• BMI calculation with documented height and weight
• Documentation of medical necessity (diagnosis or condition justifying use)
• Contraindication screening — documented clearance or explicit acknowledgment of risk
• Signed informed consent — must disclose risks, side effects, off-label use if applicable, and alternatives
• Copy of the prescription (or documentation of the prescribing provider)

Ongoing Monitoring Records

• Weight and BMI at each visit
• Adverse event log — GI symptoms, injection site reactions, any hospitalizations
• Medication lot numbers and source pharmacy for each dose administered
• Date, dose, injection site, and administering provider for every injection
• Follow-up prescriber consultation documentation at required intervals

Advertising GLP-1 Services: The FTC and FDA Guardrails

Weight loss advertising is one of the most heavily scrutinized areas in healthcare marketing. Both the FTC and FDA have specific rules that apply to med spa GLP-1 advertising:

What You CANNOT Claim

• "Lose [X] pounds in [X] weeks" — any specific outcome claim requires substantiation from adequate and well-controlled studies of your specific product/protocol
• "Guaranteed results" — no weight loss program or medication guarantees outcomes
• "Compounded Ozempic" or "compounded Wegovy" — FDA now explicitly considers using brand names for compounded products to be misleading
• "FDA-approved semaglutide" when the product is compounded — compounded drugs are not FDA-approved
• Testimonials that imply typical results without a clear "results not typical" disclosure and substantiation

What You CAN Say

• Describe the medication class accurately: "GLP-1 receptor agonist weight management program"
• Reference clinical study data with attribution: "In clinical trials, patients on semaglutide lost an average of X% body weight over 68 weeks (STEP trial, NEJM 2021)"
• Describe your program components: "medically supervised weight management with prescription GLP-1 therapy, personalized coaching, and monthly follow-ups"
• State pricing and what's included without outcome promises

Emergency Protocols for GLP-1 Adverse Events

GLP-1 medications carry specific adverse event risks that your emergency protocols must address. Your existing anaphylaxis and general emergency SOPs are not sufficient on their own — you need GLP-1-specific protocols covering:

Hypoglycemia

While GLP-1 drugs alone rarely cause hypoglycemia, patients who are also on insulin or sulfonylureas are at significant risk. Your staff must be able to:

• Recognize signs: shakiness, diaphoresis, confusion, pallor, rapid heartbeat
• Administer oral glucose (juice, glucose tablets) for mild hypoglycemia in conscious patients
• Know when to call 911 (unconscious patient, glucose not improving symptoms)
• Stock glucagon emergency kit if your patient population includes high-risk patients on combined therapy

Severe Gastrointestinal Reactions

Nausea, vomiting, and diarrhea are common GLP-1 side effects but severe reactions can lead to dehydration and electrolyte imbalance. Your protocol should cover:

• When to refer a patient to the ER (inability to tolerate any oral fluids for 24+ hours)
• Signs of pancreatitis requiring emergency referral: severe abdominal pain radiating to the back, vomiting, elevated heart rate
• Post-injection observation standards — minimum 15 minutes for first-dose patients

Injection Site Reactions

• Document all injection site reactions in the patient record
• Know the difference between normal local reaction and signs of infection (expanding erythema, warmth, fever) requiring medical evaluation
• Have a referral pathway for patients with significant reactions

Your GLP-1 Compliance Audit Checklist

Use this checklist to assess your current program. If you cannot check every item, you have compliance gaps to close before your next patient visit.

Prescribing & Clinical

• ☐ Every GLP-1 patient has a valid prescription from a licensed prescriber
• ☐ Prescriber has documented a live patient evaluation (not questionnaire-only)
• ☐ Medical necessity is documented in the patient chart
• ☐ Contraindication screening is completed and documented
• ☐ Informed consent is signed and filed — including disclosure of compounded status if applicable

Sourcing & Dispensing

• ☐ Medication is sourced from an FDA-registered 503B facility or retail pharmacy only
• ☐ You have a current FDA registration certificate on file for your compounder
• ☐ You have a Certificate of Analysis for each medication lot
• ☐ Patients are obtaining their medication from a pharmacy — you are not dispensing on-site
• ☐ You are not purchasing from any overseas or unverified online supplier

Marketing & Advertising

• ☐ No specific weight loss outcome guarantees in any marketing material
• ☐ Compounded products are not advertised using brand names (Ozempic, Wegovy, etc.)
• ☐ Testimonials include clear results-not-typical disclosure
• ☐ Website clearly discloses what is included in program fees

Operations & Protocols

• ☐ Written GLP-1 adverse event protocol exists and staff has been trained on it
• ☐ Hypoglycemia emergency supplies are stocked (glucose tablets or gel, glucagon if indicated)
• ☐ Injection lot numbers and administering provider are documented for every dose
• ☐ Florida practices: monitoring pending pharmacy licensing legislation
• ☐ Medical director has reviewed and signed off on GLP-1 program SOPs

The Bottom Line for Med Spa Operators

GLP-1 weight management services represent a significant revenue opportunity — but only for practices that operate within the law. The regulatory environment has fundamentally changed since 2024, and the practices that built their programs on compounded sourcing without updating their compliance frameworks are now exposed.

The good news: compliance is achievable without abandoning the service line. Practices that pivot to FDA-approved products, tighten their prescribing documentation, and update their marketing will be better positioned than competitors who are still playing regulatory catch-up.

The practices that will face enforcement are the ones that continue operating as if it's still 2023. Don't be that practice.